ETRA

NASD Electra Therapeutics Inc.
Oct 16, 2026 · 5:07 PM ET LAST TRADE Market Closed

$8.75 ↑ +0.00 (+0.00%) Trading Up from the previous close of $8.75, $0.40 below the day’s high of $9.16

YTD change
-33.96%
vs 20-day SMA
-18.35%
vs 200-day SMA
N/A

Price ranges

Previous day
$8.58 $8.99
open $8.97 close $8.75
-$0.22 (-2.45%)
Today
$8.50 $9.16
open $8.74 now $8.75
+$0.01 (+0.11%)
Past week
$8.50 $9.80
from $9.14 now $8.75
-$0.39 (-4.27%)
Past month
$8.50 $15.50
from $13.25 now $8.75
-$4.50 (-33.96%)
This year
$8.50 $15.50
from $13.25 now $8.75
-$4.50 (-33.96%)

Price & Performance

-4.50 (-33.96%) / 6M

$8.19$10.24$12.29$14.34Sep 18Oct 1Oct 15

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 43.5% away from all-time highs of $15.50
  • ETRA is down 34% since the beginning of the year
  • ETRA is down 34% over the past 12 months
  • ETRA is down 34% over the past 1 month
  • 2% of all ETRA investors are betting against ETRA

ETRA reads poor: the 12-month move is -34.0%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.675
Earnings momentum -57.9% Quarterly EPS growth
Quarterly change -57.9%

Valuation

P/E ratio N/A
Enterprise value $716.4M

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$86.5M
Debt$2.1K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Market cap $549.2M

Electra Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in therapies against novel targets for diseases in immunology and cancer. The company was founded by Adam Rosenthal on October 11, 2018 and is headquartered in South San Francisco, CA.

Competitor comparison

No peer group available for this symbol.

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.